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Objectives The goal of this analysis was to determine the association between intraprocedural
complications and clinical outcomes among patients with high-risk non–ST-segment elevation acute
coronary syndrome (NSTEACS) undergoing percutaneous coronary intervention (PCI).
Background Among patients undergoing PCI for NSTEACS, the relationship between intraproce-
dural complications and clinical outcomes, independent of epicardial and myocardial perfusion, has
not been well characterized.
Methods The EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute
Coronary Syndrome) trial enrolled 9,406 patients with high-risk NSTEACS undergoing an early inva-
sive strategy. Of these, 1,452 underwent angiographic assessment in an independent core laboratory
and did not have a myocardial infarction (MI) between enrollment and angiography. We assessed
the relationship between abrupt closure, loss of side branch(es), distal embolization, and no-reﬂow
phenomenon and 30-day clinical outcomes in these patients.
Results Of the patients, 166 (11.4%) experienced an intraprocedural complication. Baseline clinical char-
acteristics were similar between patients who did and did not have complications. The 30-day composite
of death or MI was signiﬁcantly higher among patients with an intraprocedural complication (28.3% vs.
7.8%, odds ratio [OR]: 4.68, 95% conﬁdence interval [CI]: 3.2 to 7.0, p  0.001). Individually, both mortal-
ity (3.0% vs. 0.9%, OR: 3.60, 95% CI: 1.2 to 10.5, p  0.019) and MI (27.1% vs. 7.4%, OR: 4.66, 95% CI: 3.1
to 7.0, p  0.001) were signiﬁcantly increased. After adjusting for differences in post-PCI epicardial and
myocardial perfusion, the association with 30-day death or MI remained signiﬁcant.
Conclusions Among high-risk NSTEACS patients undergoing an invasive strategy, the incidence of
intraprocedural complications is high, and the occurrence of these complications is associated with
worse clinical outcomes independent of epicardial and myocardial perfusion. (Early Glycoprotein
IIb/IIIa Inhibition in Patients With Non–ST-segment Elevation Acute Coronary Syndrome [EARLY ACS];
NCT00089895) (J Am Coll Cardiol Intv 2012;5:927–35) © 2012 by the American College of
Cardiology Foundation
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928Periprocedural myocardial infarction (MI), which has been
independently associated with a higher incidence of subsequent
major adverse cardiovascular events, is common among pa-
tients with non–ST-segment elevation acute coronary syn-
drome (NSTEACS) undergoing percutaneous coronary inter-
vention (PCI) (1–5). However, both the definition and clinical
significance of periprocedural MI are difficult to evaluate, as
many patients with ACS have elevated biomarkers at the time
of PCI related to their index event. Intraprocedural complica-
tions, such as loss of a coronary artery side branch, abrupt
closure, distal embolization, and the no-reflow phenomenon
can be objectively defined and occur in patients both with and
without biomarker elevation at presentation.
The EARLY ACS (Early Glycoprotein IIb/IIIa Inhibi-
tion in Non–ST-Segment Elevation Acute Coronary Syn-
drome) trial enrolled 9,406 evaluable patients with high-risk
NSTEACS undergoing an early
invasive strategy (6). The goal of
this analysis was to determine
the incidence of intraprocedural
complications and to determine
whether these complications
were associated with adverse car-
diovascular events independent
of epicardial and myocardial per-
fusion at the completion of the
procedure. An additional goal was
to determine whether the intrap-
rocedural complications were as-
sociated with adverse outcomes
independent of the patient’s base-
line troponin status prior to PCI.
Methods
Patient population. EARLY ACS
enrolled patients with high-risk
NSTEACS intended to undergo
n early invasive treatment strategy. The patient population
as been previously described (6,7). Briefly, patients who
ere at least 18 years of age were eligible if they had cardiac
schemia at rest lasting for at least 10 min and occurring
ithin 24 h before study entry, with a planned invasive
trategy no sooner than the next calendar day after random-
zation. They had to be enrolled within 8 h (12 h after a
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Abbreviations
and Acronyms
CI  confidence interval
cTFC  corrected
Thrombolysis In Myocardial
Infarction frame count
MI  myocardial infarction
NSTEACS  non–ST-segment
elevation acute coronary
syndrome
OR  odds ratio
PCI  percutaneous
coronary intervention
TFG  Thrombolysis In
Myocardial Infarction flow
grade
TIMI  Thrombolysis In
Myocardial Infarction
TMPG  Thrombolysis In
Myocardial Infarction
myocardial perfusion gradegrant support from, Amylin, Kowa Research Institute, Merck-Schering Plough, Nile,
M
arotocol amendment during the trial) of arrival in the
mergency department. Patients were considered to have a
igh-risk condition if they met 2 or more of the following
riteria: ischemic changes on electrocardiography (ST-
egment depression of 0.1 mV or more, or transient [30
in] ST-segment elevation of 0.1 mV or more in 2 or more
ontiguous leads), troponin or creatine kinase-myocardial
and (CK-MB) above the local laboratory upper limit of
ormal, and an age 60 years. A protocol amendment
uring enrollment permitted the enrollment of patients who
ere between the ages of 50 and 59 years if they had
levated levels of troponin or CK-MB and documented
oronary, cerebrovascular, or peripheral artery disease.
Study procedures. Patients in EARLY ACS were random-
ized to either double-bolus eptifibatide plus infusion or
matching placebo, in addition to standard antithrombotic
therapy, including aspirin, clopidogrel, and anticoagulant.
Before PCI, investigators could opt to use a “PCI active kit”
if they felt a glycoprotein inhibitor was needed during PCI.
In addition, investigators could request a “bailout eptifi-
batide” kit if during PCI, the subject had a thrombotic
complication and the PCI active kit had not been
administered.
Angiographic cohort. For the EARLY ACS angiographic
substudy, investigators were asked to send copies of their
patients’ angiograms to the PERFUSE Angiographic Core
Laboratory at Beth Israel Deaconess Medical Center, Har-
vard Medical School, Boston, Massachusetts. Sites were
urged to submit angiograms for this substudy. The goal was
to obtain 2,000 angiograms for analysis. From this
population, patients who did not have an MI between
enrollment and angiography were included in the current
analysis. An MI between enrollment and angiography
was defined as elevation of cardiac biomarkers above the
upper limit of normal following enrollment and before
angiography when the first set of cardiac biomarkers was
normal.
Angiographic analysis. All angiograms were evaluated inde-
endently by trained reviewers who were blinded to treat-
ent assignment, clinical and procedural data from the case
eport form, and clinical outcomes. Angiograms were eval-
ated for epicardial coronary flow using the Thrombolysis
n Myocardial Infarction (TIMI) flow grade (TFG) and the
orrected TIMI frame count (cTFC) (8,9). Myocardial
erfusion was evaluated using the TIMI myocardial perfu-
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ozen, Servier International, Johnson & Johnson, Roche, Merck, Regado, Bayer, and
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929sion grade (TMPG) (10). Angiographic perfusion score
was calculated as previously described (11). Quantitative
coronary angiography was also used to determine the
degree of coronary stenosis. Intraprocedural complica-
tions were defined as transient or sustained loss of side
branch, abrupt closure, distal embolization, and the
no-reflow phenomenon.
Loss of a side branch was defined as the development of
TFG 0 or 1 in a side branch that was 1.5 mm in diameter
before the procedure and that was initially patent with TFG
2 or 3. Distal embolization was defined as the appearance of
an abrupt cutoff in the distal vessel following PCI. No-
reflow was defined as markedly delayed flow down the artery
with minimal residual stenosis. Abrupt closure was defined
as shown in Table 1. The thrombus grade was defined as
described by Gibson et al. (12).
Statistical analysis. Baseline characteristics, angiographic
ndings, and clinical outcomes were summarized using
eans with standard deviations for continuous variables and
requencies for categorical variables. The Wilcoxon rank
um test was used for comparisons of continuous variables,
nd the chi-square or Fisher exact test was used for
omparisons of categorical variables. Odds ratios (ORs)
ith 95% confidence intervals (CIs) obtained using logistic
egression modeling were used to describe the association of
ntraprocedural complications with the 30-day composite of
eath or MI (both spontaneous and periprocedural) and
econdarily with death and MI separately. Adjusted com-
arisons considered post-PCI epicardial and myocardial
erfusion as described by TFG and TMPG. Additionally,
e assessed the association of intraprocedural complications
ith clinical outcomes after adjusting for pre-PCI troponin
tatus as reported by the individual sites, on the basis of local
aboratory findings. The p values are reported using the
og-rank test for the Kaplan-Meier failure curves. p Values
2-tailed)0.05 were considered statistically significant. No
djustments were made for multiple comparisons. All anal-
ses were performed using Stata/IC, version 10.1 (Stata-
orp, College Station, Texas).
Table 1. Definitions of Abrupt Closure
Pre-PTCA Flow Post-PTCA Flow
TFG 0 with vessel patency established (TFG 2 or 3)
during the procedure
TFG 0
TFG 1 TFG 0
TFG 2 TFG 0 or 1
TFG 3 TFG 0 or 1
PTCA  percutaneous transluminal coronary angioplasty; TFG  Thrombolysis In MyocardialwInfarction flow grade.esults
Patient population and baseline characteristics. Of 9,406
EARLY ACS patients, 1,452 did not have an MI between
enrollment and angiography, and had angiograms available
for analysis at an independent core laboratory. Baseline
clinical characteristics comparing patients who had angio-
grams available for analysis and those who did not are
shown in Table 2. Patients who had angiograms available
for analysis were, on average, younger, more likely to be
male, have dyslipidemia and elevated troponin at baseline,
and less likely to have a TIMI risk score 2, present to a
tertiary care hospital, or have a prior MI, hypertension,
creatinine clearance50 ml/min, or be in Killip class II, III,
or IV heart failure at presentation. There were also differ-
ences in the use of eptifibatide, antithrombotic therapy, and
antiplatelet therapy.
Of the 1,452 patients, 166 (11.4%) had at least 1 intrapro-
cedural complication (49.4% loss of side branch, 42.2% abrupt
closure, 30.3% distal embolization, 3.6% no-reflow; these
categories are not mutually exclusive). Among patients with
loss of a side branch, 22.0% were rescued with PCI. Of the
patients with abrupt closure, 71.4% had transient closure and
27.1% had sustained closure.
The baseline characteristics of patients with and without
intraprocedural complications are shown in Table 3. The
groups were generally similar, except that patients with an
intraprocedural complication tended to have diabetes mellitus
(p 0.07) more often and less prior PCI (p 0.07). Troponin
elevation as reported by the individual sites using local labora-
tory findings before angiography was similar between groups.
The use of bailout eptifibatide was significantly higher among
those with an intraprocedural complication.
Angiographic characteristics. Angiographic findings before
PCI are shown in Table 4. Patients who had an intrapro-
cedural complication had significantly worse pre-PCI TFG,
higher mean cTFC, and higher TMPG. In addition,
patients who experienced an intraprocedural complication
had more severe stenoses and were also more likely to have
a thrombus present.
Following PCI, patients who experienced an intraproce-
dural complication had significantly worse epicardial coro-
nary flow (TFG and cTFC), myocardial perfusion
(TMPG), and angiographic perfusion score (Table 5).
Unadjusted outcomes according to occurrence of intraprocedural
complications. Patients who had an intraprocedural com-
lication had significantly worse clinical outcomes. At 30
ays, patients who had an intraprocedural complication had
significantly higher incidence of the composite of death or
I (28.3% vs. 7.8%, OR: 4.68, 95% CI: 3.2 to 7.0, p 
.001) (Fig. 1A). Individually, both mortality (3.0% vs.
.9%, OR: 3.60, 95% CI: 1.2 to 10.5, p  0.019) and MI
27.1% vs. 7.4%, OR: 4.66, 95% CI: 3.1 to 7.0, p  0.001)
ere also significantly increased among patients who had an
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930intraprocedural complication (Figs. 1B and 1C). At 1 year,
the difference in mortality was no longer significant (3.01%
vs. 3.90%, p  0.58).
Table 2. Baseline Clinical Characteristics: Angiography Versus No Angiogr
Characteristic
Age, yrs
Female
Region of enrollment
North America
Western Europe
Eastern Europe
Middle East, Africa, or Asia-Paciﬁc
Medical history
Diabetes mellitus
Dyslipidemia
Hypertension
Previous CABG
Previous MI
Previous PCI
Creatinine clearance 50 ml/min
Killip class II, III, or IV
Qualifying high-risk features
Age 60 yrs, elevated biomarkers, and ST-segment changes
Age 60 yrs and elevated biomarkers
Elevated biomarkers and ST-segment changes
Age 60 yrs and ST-segment changes
Age 50–59 yrs, elevated biomarkers, and previous vascular disease
Elevated troponin
Presentation to tertiary care hospital
TIMI risk score
0–2
3–4
5–7
Medical therapy during hospitalization
Randomized to early eptiﬁbatide
PCI active eptiﬁbatide kit used
Antithrombin therapy
UFH
LMWH
UFH and LMWH
Neither UFH nor LMWH
Aspirin
Clopidogrel
At any time
Early use intended
Beta-blocker
Statin
ACE inhibitor
ARB
Values are mean SD or n (%).
ACE angiotensin-converting enzyme; ARB angiotensin-receptor blocker; CABG coronary acoronary intervention; TIMI Thrombolysis In Myocardial Infarction; UFH unfractionated heparin.As the number of intraprocedural complications increased,
the rate of the composite of death or MI increased from 7.6%
(97 of 1,275) for patients with no complications to 24.8% (32
r MI Before Angiography
study Cohort
 1,452)
No Angiogram Available
or Intervening MI
(n  7,954) p Value
66.310.5 67.210.7 0.001
385 (26.5%) 2,590 (32.6%) 0.001
0.001
403 (27.8%) 2,485 (31.2%)
419 (27.9%) 3,371 (42.4%)
99 (6.8%) 919 (11.6%)
531 (36.6%) 1,179 (14.8%)
429 (29.6%) 2,431 (30.6%) 0.44
893 (61.5%) 4,547 (57.2%) 0.002
968 (66.7%) 5,730 (72.0%) 0.001
203 (14.0%) 1,079 (13.6%) 0.67
360 (24.8%) 2,235 (28.1%) 0.009
401 (27.6%) 1,919 (24.1%) 0.005
230 (16.2%) 1,436 (18.7%) 0.021
127 (8.8%) 915 (11.6%) 0.002
0.001
270 (18.6%) 1,701 (21.4%)
634 (43.7%) 3,311 (41.6%)
219 (15.1%) 1,140 (14.3%)
127 (8.8%) 914 (11.5%)
97 (6.7%) 445 (5.6%)
,251 (88.1%) 6,399 (83.1%) 0.001
,106 (76.2%) 6,530 (82.1%) 0.001
0.001
301 (21.1%) 1,220 (15.7%)
682 (47.7%) 3,733 (48.1%)
447 (31.3%) 2,811 (36.2%)
734 (50.6%) 3,988 (50.1%) 0.77
658 (45.3%) 1,518 (19.1%) 0.001
0.001
430 (29.6%) 2,807 (35.3%)
846 (58.3%) 4,127 (51.9%)
121 (8.3%) 528 (6.6%)
55 (3.8%) 492 (6.2%)
,419 (98.5%) 7,647 (97.1%) 0.002
,440 (99.2%) 7,058 (88.8%) 0.001
,178 (81.1%) 5,879 (73.9%) 0.001
,291 (89.9%) 6,944 (87.3%) 0.088
,295 (89.2%) 6,841 (86.0%) 0.001
988 (68.0%) 5,454 (68.6%) 0.69
139 (9.6%) 787 (9.9%) 0.71
pass graft; LMWH lowmolecular weight heparin; MImyocardial infarction; PCI percutaneousaphy o
Sub
(n
1
1
1
1
1
1
1
rtery by
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931of 129) for patients with 1 complication to 38.9% (14 of 36)
among patients with more than 1 intraprocedural complication
(p  0.001 for all comparisons) (Fig. 2).
Table 3. Baseline Clinical Characteristics: Intraprocedural Complication Ve
Characteristic
Age, yrs
Female
Region of enrollment
North America
Western Europe
Eastern Europe
Middle East, Africa, or Asia-Paciﬁc
Medical history
Diabetes mellitus
Dyslipidemia
Hypertension
Previous CABG
Previous MI
Previous PCI
Creatinine clearance 50 ml/min
Killip class II, III, or IV
Qualifying high-risk features
Age 60 yrs, elevated biomarkers, and ST-segment changes
Age 60 yrs and elevated biomarkers
Elevated biomarkers and ST-segment changes
Age 60 yrs and ST-segment changes
Age 50–59 yrs, elevated biomarkers, and previous vascular disease
Elevated troponin
Presentation to tertiary care hospital
TIMI risk score
0–2
3–4
5–7
Medical therapy during hospitalization
Antithrombin therapy
UFH
LMWH
UFH and LMWH
Neither UFH or LMWH
Aspirin
Clopidogrel
At any time
Early use intended
Beta-blocker
Statin
ACE inhibitor
ARB
Randomized to early eptiﬁbatide
PCI active eptiﬁbatide kit used
Use of bailout eptiﬁbatide
Values are mean or n (%).Abbreviations as in Table 2.When patients were stratified by troponin elevation prior
to PCI, the incidence of the composite of death or MI again
was significantly higher among patients who had an intrap-
None
traprocedural
Complication
(n  166)
No Intraprocedural
Complication
(n  1,286) p Value
66.610.7 66.210.5 0.68
45 (27.1%) 340 (26.4%) 0.85
0.53
43 (25.9%) 360 (28.0%)
56 (33.7%) 363 (28.2%)
10 (6.0%) 89 (6.9%)
57 (34.3%) 474 (36.9%)
59 (35.5%) 370 (28.8%) 0.07
94 (56.6%) 799 (62.2%) 0.17
111 (66.9%) 857 (66.6%) 0.95
26 (15.7%) 177 (13.8%) 0.51
48 (28.9%) 312 (24.3%) 0.19
36 (21.7%) 365 (28.4%) 0.07
29 (17.9%) 201 (15.9%) 0.520
15 (9.1%) 112 (8.8%) 0.90
0.63
30 (18.1%) 240 (18.7%)
75 (45.2%) 559 (43.5%)
30 (18.1%) 189 (14.7%)
12 (7.2%) 115 (9.0%)
7 (4.2%) 90 (7.0%)
145 (89.0%) 1,106 (88.0%) 0.72
126 (75.9%) 980 (76.2%) 0.93
0.61
30 (18.3%) 271 (21.4%)
83 (50.6%) 599 (47.3%)
51 (31.1%) 396 (31.3%)
0.37
54 (32.5%) 376 (29.2%)
87 (52.4%) 759 (59.0%)
18 (10.8%) 103 (8.0%)
7 (4.2%) 48 (3.7%)
162 (99.4%) 1,257 (98.4%) 0.50
165 (99.4%) 1,275 (99.1%) 1.000
139 (83.7%) 1,039 (80.8%) 0.36
148 (89.2%) 1,143 (88.9%) 0.92
143 (86.1%) 1,152 (89.6%) 0.18
115 (69.3%) 873 (67.9%) 0.72
18 (10.8%) 121 (9.4%) 0.55
69 (41.6%) 665 (51.7%) 0.01
102 (61.4%) 556 (43.2%) 0.001
64 (8.1%) 102 (15.5%) 0.001rsus
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932rocedural complication, both among those with (n  1,251,
6.2% vs. 8.1%, OR: 4.01, 95% CI: 2.6 to 6.2, p  0.001)
nd those without (n 169, 44.4% vs. 5.3%, OR: 14.3, 95%
I: 4.4 to 46.1, p 0.001) elevated troponin (p 0.046 for
interaction). Patients who experienced an intraprocedural
complication with (2.8% vs. 1.0%, OR: 2.82, 95% CI: 0.9 to
9.0, p  0.079) and without (5.6% vs. 0%, p  0.004)
elevated troponin at enrollment had higher 30-day mortal-
ity. The findings were similar for MI alone (25.5% vs. 7.7%,
OR: 4.11, 95% CI: 2.7 to 6.4, p  0.001 among those with
elevated troponin; 38.9% vs. 5.3%, OR: 11.38, 95% CI: 3.5
to 37.2, p  0.001 among those with normal troponin; p 
0.11 for interaction).
The analysis was then restricted to patients with a patent
infarct-related artery before PCI (TFG: 2 or 3, n  1,152).
Table 4. Angiographic Findings Prior to PCI
Intraprocedural
Complication
(n  166)
No Intraprocedural
Complication
(n  1,286) p Value
Culprit lesion location 0.38
LAD 43 (25.9%) 418 (32.5%)
LCX 51 (30.7%) 377 (29.3%)
RCA 50 (30.1%) 356 (27.7%)
LM 3 (1.8%) 9 (0.7%)
Diagonal 3 (1.8%) 28 (2.2%)
SVG 16 (9.6%) 96 (7.5%)
Pre-PCI TIMI ﬂow grade 0.001
0/1 44 (27.0%) 221 (17.6%)
2 43 (26.4%) 255 (20.3%)
3 76 (46.6%) 778 (62.0%)
Pre-PCI corrected TIMI
frame count
38.9 (21.6%) 34.0 (19.5%) 0.03
Pre-PCI TIMI myocardial
perfusion grade
0.001
0/1 89 (59.3%) 580 (49.8%)
2 8 (5.3%) 17 (1.5%)
3 53 (35.3%) 567 (48.7%)
2/3 61 (40.7%) 584 (50.2%) 0.03
Pre-PCI MLD, mm 0.420.34 0.530.41 0.001
Pre-PCI % stenosis 84.711.9 80.013.8 0.001
Pre-PCI reference diameter, mm 2.660.71 2.630.72 0.30
Pre-PCI thrombus grade 0.02
0 63 (38.2%) 643 (50.2%)
1 34 (20.6%) 266 (20.8%)
2 6 (3.6%) 44 (3.4%)
3 14 (8.5%) 95 (7.4%)
4 6 (3.6%) 36 (2.8%)
5 42 (25.5%) 193 (15.1%)
6 0 4 (0.3%)
Values are mean SD or n (%).
LAD left anterior descending coronary artery; LCX left circumflex coronary artery; LM
left main coronary artery; MLD  minimal lumen diameter; RCA  right coronary artery;
SVG  saphenous vein graft; other abbreviations as in Table 2.The incidence of the composite of death or MI at 30 dayswas significantly higher among patients who experienced an
intraprocedural complication (32.8% vs. 7.8%, OR: 5.73,
95% CI: 3.7 to 8.9, p  0.001). The same held true when
evaluating death (4.2% vs. 0.6%, OR: 7.51, 95% CI: 2.3 to
25.0, p  0.001) and MI (31.1% vs. 7.6%, OR: 5.52, 95%
CI: 3.5 to 8.7, p  0.001) alone.
Adjusted outcomes according to occurrence of intraprocedural
complications. After adjusting for differences in parameters
f epicardial and myocardial perfusion following PCI as well
s elevated troponin before PCI, the relationship between
ntraprocedural complications and the composite of death or
I at 30 days remained significant (adjusted OR [ORadj]:
.56, 95% CI: 2.2 to 5.7, p 0.001). The same held true for
I (ORadj: 3.58, 95% CI: 2.2 to 5.8, p  0.001) alone, but
the difference in mortality alone was directionally similar but
no longer statistically significant (ORadj: 2.30, 95% CI: 0.5
o 10.2, p  0.27).
iscussion
Intraprocedural complications occurred in more than 11%
of patients with NSTEACS undergoing an early invasive
strategy. Such complications were associated with a more
than 4-fold increase in the risk of death or spontaneous or
periprocedural MI at 30 days, even after adjusting for
differences in post-PCI epicardial flow and myocardial
perfusion and elevated troponin before PCI. Further, the
greater the number of intraprocedural complications, the
worse were the clinical outcomes. Among patients with a
patent artery before PCI, the relationship between intra-
procedural complications and the risk of 30-day death or
Table 5. Post-PCI Angiographic Results
Intraprocedural
Complication
(n  166)
No Intraprocedural
Complication
(n  1,286) p Value
Post-PCI TIMI ﬂow grade 0.001
0/1 28 (17.3%) 28 (2.2%)
2 15 (9.3%) 74 (5.9%)
3 119 (73.5%) 1,155 (91.9%)
Post-PCI corrected TIMI
frame count
25.9 14.1 23.3 14.0 0.055
Post-PCI TIMI myocardial
perfusion grade
0.001
0/1 92 (65.7%) 423 (42.3%)
2 8 (5.7%) 30 (3.0%)
3 40 (28.6%) 546 (54.7%)
2/3 92 (65.7%) 423 (42.3%) 0.001
Angiographic perfusion
score
0.001
0–3 20 (15.2%) 37 (3.9%)
4–9 75 (56.8%) 438 (46.4%)
10–12 37 (28.0%) 469 (49.7%)
Values are mean or n (%).Abbreviations as in Table 2.
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933MI remained significant. Moreover, there was a strong
relationship between intraprocedural complications and 30-
day outcomes among patients with and without elevated
troponin before PCI. These results from a blinded angio-
graphic core laboratory build upon results of previous
analyses using site investigator–reported angiographic com-
plications and clinical outcomes, and suggest a potential role
for intraprocedural complications as an intermediate end-
point in clinical trials (13).
Elevated cardiac biomarkers following PCI in patients
who already have elevated biomarkers before the procedure
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Figure 1. Estimates of the Rate of the Composite of Death or MI
Kaplan-Meier estimates of the rate of the composite of death and myocar-
dial infarction (MI) (A), mortality (B), and myocardial infarction (C) compar-
ing patients with and without intraprocedural complications (loss of side
branch, abrupt closure, distal embolization, and the no-reﬂow phenome-
non). OR  unadjusted odds ratio.may represent the consequence of myocardial injury andbiomarker release both before and following the procedure.
The relative contribution of pre-procedure biomarker re-
lease can therefore confound the interpretation of biomarker
elevations following PCI, including the assessment of the
association of procedure-related biomarkers with subse-
quent ischemic outcomes. The present study indicates that
independent of troponin elevation before PCI, the occur-
rence of a complication during the procedure is associated
with an increased risk of adverse events during follow-up,
including mortality.
This angiographic endpoint also provides additional
prognostic information independent of epicardial flow and
downstream myocardial perfusion. Indeed, closure of side
branches may not be counted as an adverse outcome using
traditional measures of angiographic success, which focus
exclusively on outcomes in the parent artery or distal to the
parent artery. Cardiovascular magnetic resonance imaging
data indicate that hyperenhancement consistent with myo-
necrosis may occur not only distal to the parent artery,
presumably due to embolization, but also adjacent to the
parent artery in the vicinity of branches (14). Side branches
are frequently present at the site of culprit lesions in patients
with ACS (15), and in this setting, side branch occlusion
may occur in more than 20% of patients, most commonly
following stent dilation (15,16). In the present study, about
one-quarter of occluded side branches were successfully
recanalized with PCI.
Both patients with and without troponin elevation before
PCI had a significantly higher composite of death and MI.
Patients without troponin elevation before PCI who had an
intraprocedural complication had a much higher increase in
the risk of death and MI than those with elevation of cardiac
biomarkers before PCI. This may be the play of chance, as
there were far more patients with normal cardiac bio-
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Figure 2. Rate of the Composite of Death or MI by Number
of Complications
There was a step-wise increase in the risk of the composite of death or
myocardial infarction (MI) as the number of thrombotic complications
increased in a given patient. OR  odds ratio.
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934markers before PCI. However, 1 potential reason for this
finding is that patients who are already having an MI
have less myocardium at risk in the downstream territory,
and patients who have a periprocedural MI when no MI
was ongoing lose more myocardium.
Abrupt closure occurs in about 3% to 6% of PCIs and is
more common after balloon angioplasty than stent implanta-
tion (17,18). In prior studies, abrupt closure was associated
with periprocedural MI in approximately 5% of patients and an
in-hospital mortality of approximately 2% (17). In the present
study, abrupt closure was transient in three-quarters of pa-
tients, having resolved by the end of the case.
Distal embolization is common among patients undergo-
ing PCI, especially during ACS. Predictors of distal embo-
lization are largely related to plaque burden and constitu-
tion. A larger necrotic core, the presence of thrombus, a thin
fibrous cap atheroma, and large lipid arc size detected via
intravascular ultrasound and optical coherence tomography
have been strongly associated with a higher incidence of
distal embolization and the no-reflow phenomenon (18–20).
The occurrence of no-reflow in contemporary treatment of
ACS patients may be as high as 35%, although its incidence
is significantly higher among ST-segment elevation MI
patients undergoing primary PCI (21). It is likely related to
a combination of distal embolization, ischemia-related in-
jury, and reperfusion-related injury (21), and it has been
strongly related to adverse clinical outcomes (22–24).
Prior clinical outcomes studies among patients with stable
coronary artery disease and ACS undergoing PCI have focused
largely on a periprocedural rise in cardiac biomarkers as a
surrogate outcome. However, particularly among patients with
NSTEACS, increased cardiac biomarkers measured following
PCI may be the result of ongoing myocardial necrosis that
occurred as a consequence of their presenting ACS itself rather
than as a result of the PCI. Intraprocedural complications are
objective, definable outcomes that the current study suggests
are clinically relevant.
Study limitations. Several limitations are acknowledged.
This is a small subset from a randomized controlled trial,
and the population may be inherently different from a
real-world population. Patients included in this analysis
were from a convenience sample of angiograms, and so were
significantly different from the population enrolled in
EARLY ACS as a whole. Although this does not alter the
significant relationship between complications and out-
comes, it is an acknowledged limitation of the study. The
patients in the present study were high-risk NSTEACS
patients, and it is unknown whether these findings would
apply to patients with stable coronary disease undergoing
elective procedures or those with ST-segment elevation MI.
Because the groups we compared were formed on the basis
of whether or not complications occurred, and patients were
treated according to local standard of care, there were likely
inherent baseline differences between the cohorts, due tounmeasured confounders. These differences may have led to
the occurrence of intraprocedural complications or may have
led to differences in treatment strategies after the procedure
that influenced outcomes. In particular, physician behavior,
which may be dictated by any of a number of factors,
including regional or local practice patterns or operator,
patient, or lesion characteristics, may have been important
considerations but were not measured. Therefore, these
findings should be validated in other cohorts.
Conclusions
Among patients with NSTEACS undergoing an early
invasive strategy, intraprocedural complications (loss of side
branch, abrupt closure, distal embolization, and the no-
reflow phenomenon) occurred in more than 11% of patients
and were associated with a more than 4-fold increase in the
composite of death or MI at 30 days, even after adjusting for
differences in post-PCI TFG and TMPG and elevated
troponin before PCI. Intraprocedural complications are
objective, definable outcomes that should be considered as
intermediate endpoints in future clinical trials.
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